- Home
- NAAS vs DXR Comparison
NAAS vs DXR Comparison
Compare NAAS & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAAS
- DXR
- Stock Information
- Founded
- NAAS 2019
- DXR 1970
- Country
- NAAS China
- DXR United States
- Employees
- NAAS N/A
- DXR N/A
- Industry
- NAAS Other Specialty Stores
- DXR Medical/Dental Instruments
- Sector
- NAAS Consumer Discretionary
- DXR Health Care
- Exchange
- NAAS Nasdaq
- DXR Nasdaq
- Market Cap
- NAAS 40.1M
- DXR 42.6M
- IPO Year
- NAAS 2017
- DXR N/A
- Fundamental
- Price
- NAAS $2.91
- DXR $9.01
- Analyst Decision
- NAAS
- DXR Strong Buy
- Analyst Count
- NAAS 0
- DXR 1
- Target Price
- NAAS N/A
- DXR $24.75
- AVG Volume (30 Days)
- NAAS 141.1K
- DXR 7.6K
- Earning Date
- NAAS 11-20-2024
- DXR 01-01-0001
- Dividend Yield
- NAAS N/A
- DXR N/A
- EPS Growth
- NAAS N/A
- DXR N/A
- EPS
- NAAS N/A
- DXR 0.35
- Revenue
- NAAS $58,241,066.00
- DXR $154,205.00
- Revenue This Year
- NAAS $19.53
- DXR N/A
- Revenue Next Year
- NAAS $151.36
- DXR N/A
- P/E Ratio
- NAAS N/A
- DXR $25.85
- Revenue Growth
- NAAS 199.95
- DXR N/A
- 52 Week Low
- NAAS $1.42
- DXR $7.11
- 52 Week High
- NAAS $59.20
- DXR $10.04
- Technical
- Relative Strength Index (RSI)
- NAAS 45.72
- DXR 49.80
- Support Level
- NAAS $2.50
- DXR $8.53
- Resistance Level
- NAAS $2.95
- DXR $9.10
- Average True Range (ATR)
- NAAS 0.22
- DXR 0.47
- MACD
- NAAS 0.01
- DXR -0.01
- Stochastic Oscillator
- NAAS 56.10
- DXR 35.71
About NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators. wide range of offline services that simplify the daily operations of charging station operators, and of non-charging services such as food and beverage services to station operators.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.